Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2000

View Archived Issues

Cialis shows promise as ED therapy in phase II

Cangene's newest hyperimmune agent targets hepatitis C

Proinflammatory cytokines downregulated by Vasogen's immune modulation therapy

Research on Alteon's ALT-711 fueled by ADA grant; phase IIa trial on target

Genzyme acquisition of GelTex complete

SB returns to Aradigm control of phase II development of pain management system

Putative antidepressant LY-367265 exerts dual 5-HT2A receptor/5-HT transporter-antagonist effects

New company formed to develop diagnostics for prion diseases

Schering AG and Jenapharm jointly develop highly potent, selective and pure progesterone antagonist

Synsorb Biotech suspends Synsorb Pk development; Synsorb Cd moves forward

Novartis seeks FDA approval for nonsteroidal eczema therapy

Factive denied approval by FDA

NicOx advances three products into phase I clinical trials

CPMP recommends approval of Visudyne therapy for treatment of pathological myopia

Micrologix moves antiinfective agent to phase III

Data support development of Vical's gene-based cancer therapies

Phase I clinical trial on gene therapy for HIV+ children begins in L.A.

Multitargeted antifolate as salvage therapy in refractory/resistant metastatic breast cancer

Combinations of exisulind and Herceptin or Taxotere synergistic in human breast cancer cells

R-115777: an oral protein farnesyltransferase inhibitor with activity in advanced breast cancer

New retinoid-like compounds described by Allergan

Treatments for inflammatory disorders in development at Aventis inhibit cell adhesion

R&D at Texas Biotechnology leads to identification of new integrin inhibitors

Bayer's new antiviral agents particularly useful against HCMV infections

PDE7 inhibitors and their use presented by Darwin Discovery

Neurogen scientists claim new series of GABA-A receptor ligands

Antibacterial agents with quinolone-based structure designed at Japanese lab

Kaken patents new series with potential utility in inflammation, osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...